BioStem Technologies, Inc. announced that company management will present at the 46th Annual TD Cowen Healthcare Conference in Boston, Massachusetts. The presentation is scheduled for Monday, March 2, 2026, at 3:50 pm Eastern Time. This appearance at a prominent investment conference provides BioStem with a platform to communicate its business strategy and technological developments to the financial community. The presentation at the TD Cowen conference represents a significant opportunity for BioStem to engage with investors and analysts during a period of growth in the regenerative medicine sector.
The company specializes in developing, manufacturing, and commercializing perinatal tissue-derived products for advanced wound care. Its focus on regenerative therapies utilizes tissue allografts processed through its proprietary BioRetain® method. This technology aims to maintain growth factors and preserve tissue structure, which are critical for effective healing applications. The company's operations comply with current Good Tissue Practices and current Good Manufacturing Processes, and its systems are accredited by the American Association of Tissue Banks. BioStem's product portfolio includes several brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and the Neox® and Clarix® product lines. These products are designed to address complex wound care needs through biological solutions.
The company's emphasis on perinatal tissue products positions it within a specialized niche of the medical technology market. Interested parties can access a live webcast of the conference presentation, along with an archived version, through the investors section of the company's website at https://ir.biostemtechnologies.com. For additional information about the company and its products, visit https://biostemtechnologies.com. The latest company news and updates are also available through its newsroom at https://tinyurl.com/bsemnewsroom.
